LA JOLLA, Calif., March 18 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced that Dr. Juliet Singh, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Thursday, March 20, 2008 at 10:15 a.m. Eastern Time at The Marriott Copley Place in Boston, MA.
Dr. Singh will discuss the Company's business developments to date including the recent submission of the Phase 3 clinical study of Ketotransdel(TM) to the FDA.
Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com. An archived presentation will be available on the Web site for 30 days.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel(TM), utilizes the Company's innovative patented proprietary Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas.
Safe Harbor Statement
The statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of
economic conditions and other uncertainties detailed in the Company's
filings with the Securities and Exchange Commission.
Chief Financial Officer
Transdel Pharmaceuticals, Inc.
|SOURCE Transdel Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved